Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenezumab long-term safety extension in Alzheimer's disease
NCT01723826Phase 2Completed
- Sponsor
- Genentech
- Start
- Dec 2012
- Primary completion
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of crenezumab in Alzheimer's disease (AD), sponsored by Genentech. Started Dec 2012; status: completed.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01723826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01723826.